MDS Pharma Services Expands Central Lab Operations in China
30 Octobre 2007 - 1:00PM
PR Newswire (US)
Testing capacity increased five-fold to meet growing demands KING
OF PRUSSIA, PA, Oct. 30 /PRNewswire-FirstCall/ -- MDS Pharma
Services, a leading provider of innovative drug discovery and
development solutions, announced today a significant expansion of
its central lab operations in China. The contract research
organization has moved to a new, larger facility in Beijing to meet
the growing demands from pharmaceutical and biotech companies
conducting clinical trials in China. With almost 25,000 square
feet, the new facility offers a five-time increase in testing
capacity, four times the space to produce clinical trial kits, and
a wider range of specialized clinical trial testing services. This
new facility's proximity to the Beijing airport also facilitates
faster transportation of clinical trial samples. "We are excited
about how this significant expansion will better serve the growing
needs of our clients," said MDS Pharma Services President David
Spaight. "With many pharmaceutical and biotech companies now making
China part of their global clinical trial programs, we recognized
the need to expand our central lab operations and offer more
diverse testing options." This new central lab facility specializes
in molecular biology testing for infectious diseases, DNA banking
and pharmacogenomics - the study of genes to develop therapies
tailored to a person's genetic makeup. It also offers enhanced
molecular biology techniques, a microbiology lab and flow cytometry
capabilities - a technology used increasingly in oncology and
immune disorders. MDS Pharma Services continues to offer project
and data management from this new facility. MDS Pharma Services has
been in China for more than 10 years and has managed more than
30,000 patients in clinical trials. As an industry pioneer, it
introduced standardized clinical research services to China. It was
the first western contract research organization to own its
facility in China and the first clinical laboratory in China to
receive accreditation from the College of American Pathologists. It
also maintains the National Glycohemoglobin Standardization Program
Level I certification. In addition to the Beijing site, MDS Pharma
Services offers central laboratory services in key geographic areas
around the world, including Canada, the United States, France,
Germany, Singapore and South America. About MDS Pharma Services MDS
Pharma Services offers a full spectrum of resources to meet the
drug discovery and development needs of the pharmaceutical and
biotechnology industries. With numerous facilities strategically
located around the world, we apply advanced scientific and
technological expertise throughout the drug discovery and
development process - from lead optimization, pre-IND research,
early clinical research (bioequivalence, phases I-IIa) and
bioanalysis through to global clinical development (phases IIb-IV),
central lab and centralized cardiac services. For more information,
visit our website at http://www.mdsps.com/. MDS Pharma Services is
a business unit of MDS Inc. (TSX: MDS; NYSE: MDZ), a global life
sciences company that provides market-leading products and services
that our customers need for the development of drugs and diagnosis
and treatment of disease. We are a leading global provider of
pharmaceutical contract research, medical isotopes for molecular
imaging, radiotherapeutics, and analytical instruments. MDS has
more than 6,200 highly skilled people in 28 countries. Find out
more at http://www.mdsinc.com/ or by calling 1-888-MDS-7222, 24
hours a day.
http://www.newscom.com/cgi-bin/prnh/20071030/MDSPHARMALAB/TO267
http://photoarchive.ap.org/ DATASOURCE: MDS Pharma Services
CONTACT: Investors, Sharon Mathers, (416) 675-6777, ext. 34721, ;
Media, Charlene McGrady, (610) 239-7900, ext. 231,
Copyright